{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:13:28Z","timestamp":1771632808446,"version":"3.50.1"},"reference-count":26,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T00:00:00Z","timestamp":1645401600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Virology"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:label\/><jats:p>The study aimed to assess the adverse events following COVID\u201019 vaccine (Covaxin) immunization at a tertiary care institution and also assess the predictors of the adverse events following immunization (AEFI). The prospective observational study was conducted in a tertiary care institute among the Covaxin beneficiaries between June 28 and September 6, 2021. A total of 1826 participants were assessed for any local or systemic adverse events after seven days of vaccination. A telephonic interview was conducted, and the beneficiaries were assessed according to the adverse event grading. A total of 1826 participants were assessed for AEFI, and 544 (29.8%) reported at least one of the AEFI. No severe adverse events were reported, and about 1.6% had moderate AEFI. Pain at the injection site (14.6%), fever (9.7%), and myalgia (5.9%) were the common adverse events reported by the participants. AEFI incidence was higher in the first dose (38.1%) when compared to the second dose (26.4%), and this finding was significant with a p\u2009&lt;\u20090.001. The major factors associated with AEFI were female sex, history of an allergic reaction, presence of comorbidities, acute infection in the past 3 months, and intake of chronic medications. Precaution needs to be taken while vaccinating individuals having allergies, comorbidities, acute infection in the last 3 months, and individuals on chronic medication.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jmv.27655","type":"journal-article","created":{"date-parts":[[2022,2,12]],"date-time":"2022-02-12T02:28:30Z","timestamp":1644632910000},"page":"2453-2459","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Adverse events following immunization of COVID\u201019 (Covaxin) vaccine at a tertiary care center of India"],"prefix":"10.1002","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0809-4588","authenticated-orcid":false,"given":"Swayam Pragyan","family":"Parida","sequence":"first","affiliation":[{"name":"Department of Community Medicine and Family Medicine All India Institute of Medical Sciences Bhubaneswar Odisha India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8044-3159","authenticated-orcid":false,"given":"Dinesh Prasad","family":"Sahu","sequence":"additional","affiliation":[{"name":"Department of Community Medicine and Family Medicine All India Institute of Medical Sciences Bhubaneswar Odisha India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7063-7435","authenticated-orcid":false,"given":"Arvind Kumar","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Community Medicine and Family Medicine All India Institute of Medical Sciences Bhubaneswar Odisha India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8980-6734","authenticated-orcid":false,"given":"G.","family":"Alekhya","sequence":"additional","affiliation":[{"name":"Department of Community Medicine and Family Medicine All India Institute of Medical Sciences Bhubaneswar Odisha India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5598-9088","authenticated-orcid":false,"given":"Sonu Hangma","family":"Subba","sequence":"additional","affiliation":[{"name":"Department of Community Medicine and Family Medicine All India Institute of Medical Sciences Bhubaneswar Odisha India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4745-3379","authenticated-orcid":false,"given":"Abhisek","family":"Mishra","sequence":"additional","affiliation":[{"name":"Department of Community Medicine and Family Medicine All India Institute of Medical Sciences Bhubaneswar Odisha India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biswa Mohan","family":"Padhy","sequence":"additional","affiliation":[{"name":"Department of Pharmacology All India Institute of Medical Sciences Bhubaneswar Odisha India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0019-4522","authenticated-orcid":false,"given":"Binod Kumar","family":"Patro","sequence":"additional","affiliation":[{"name":"Department of Community Medicine and Family Medicine All India Institute of Medical Sciences Bhubaneswar Odisha India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,2,21]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"WHO. Coronavirus Disease (COVID\u201019) Dashboard WHO Coronavirus Disease (COVID\u201019) Dashboard.\u00a0 Accessed September 20 2021.\u00a0https:\/\/covid19.who.int\/"},{"key":"e_1_2_10_3_1","unstructured":"Ministry of Health and Family Welfare Government of India. COVID\u201019 India. Accessed September 20 2021.\u00a0https:\/\/www.mohfw.gov.in\/"},{"key":"e_1_2_10_4_1","unstructured":"Ministry of Science and Technology. DBT\u2010BIRAC supported ZyCoV\u2010D developed by Zydus Cadila Receives Emergency Use Authorization. Press Information Bureau. Accessed September 20 2201.\u00a0https:\/\/pib.gov.in\/PressReleasePage.aspx?PRID=1747669"},{"key":"e_1_2_10_5_1","unstructured":"Press Information Bureau. PIB'S bulletin on COVID\u201019. PIB headquarters. Accessed September 20 2021.https:\/\/pib.gov.in\/PressReleasePage.aspx?PRID=1743567"},{"key":"e_1_2_10_6_1","unstructured":"Ministry of Health and Family Welfare. The national regulator grants permission for restricted use in emergency situations to Sputnik\u2010V vaccine. Press Information Bureau. Accessed September 20 2021.\u00a0https:\/\/pib.gov.in\/PressReleasePage.aspx?PRID=1711342"},{"key":"e_1_2_10_7_1","unstructured":"PM to launch Pan India Rollout of COVID\u201019 vaccination drive on January 16.\u00a0Over 3000 sites across all States and UTs to be virtually connected during the launch around 100 beneficiaries to be vaccinated at each site on the inaugural day. Press Information Bureau Government of India; 2021. Accessed February 22 2021.https:\/\/pib.gov.in\/PressReleaseIframePage.aspx?PRID=1688607#"},{"key":"e_1_2_10_8_1","unstructured":"Press Information Bureau Government of India. Ministry of Health & Family Welfare Government of India.\u00a0Accessed May 9 2021.https:\/\/pib.gov.in\/PressReleseDetail.aspx?PRID=1703346"},{"key":"e_1_2_10_9_1","unstructured":"Ministry of Health & Family Welfare Government of India.\u00a0Accessed September 20 2021.https:\/\/www.cowin.gov.in\/home"},{"key":"e_1_2_10_10_1","unstructured":"World Health Organization.2018. Accessed September 20 2021.https:\/\/www.who.int\/vaccine_safety\/initiative\/tech_support\/Part\u20103.pdf?ua=1"},{"key":"e_1_2_10_11_1","unstructured":"Ministry of Health & Family Welfare Government of India. Accessed May 9 2021.https:\/\/www.cowin.gov.in\/faq"},{"key":"e_1_2_10_12_1","first-page":"637","article-title":"Safety and immunogenicity of an inactivated SARS\u2010CoV\u20102 vaccine, BBV152: a double\u2010blind, randomised, phase 1 trial","volume":"21","author":"Ramanathan K","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"e_1_2_10_13_1","unstructured":"US FDA. Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. Accessed September 2007.\u00a0http:\/\/www.fda.gov\/cber\/guidelines.htm"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00224-3"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mjafi.2021.06.014"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00070-0"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32466-1"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034201"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31605-6"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.101038"},{"key":"e_1_2_10_21_1","article-title":"Serious adverse events reported from the COVID\u201019 vaccines: a descriptive study based on WHO database","author":"Dutta S","journal-title":"medRxiv Prepr"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s42399-021-01021-z"},{"issue":"1","key":"e_1_2_10_23_1","first-page":"9","article-title":"Adverse events following the first dose of ChAdOx1 nCoV\u201019 (COVISHIELD) vaccine in the first phase of vaccine roll out in Nepal","volume":"19","author":"Shrestha S","year":"1886","journal-title":"JPAHS"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2021.36.e107"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.3390\/life11030249"},{"key":"e_1_2_10_26_1","first-page":"6","article-title":"Higher incidence of reported adverse events following immunisation (AEFI) after first dose of COVID\u201019 vaccine among previously infected health care workers","volume":"7","author":"Joshi A","year":"2019","journal-title":"Med J Armed Forces India"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40249-021-00878-5"}],"container-title":["Journal of Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.27655","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jmv.27655","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.27655","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T14:45:26Z","timestamp":1692974726000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jmv.27655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,21]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1002\/jmv.27655"],"URL":"https:\/\/doi.org\/10.1002\/jmv.27655","archive":["Portico"],"relation":{},"ISSN":["0146-6615","1096-9071"],"issn-type":[{"value":"0146-6615","type":"print"},{"value":"1096-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,21]]},"assertion":[{"value":"2021-12-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}